Completed NA INTERVENTIONAL NCT00398372

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Sponsor: Amgen

Conditions Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin Lymphomas: Non-Hodgkin Cutaneous Lymphoma Lymphomas: Non-Hodgkin Diffuse Large B-Cell Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell Lymphomas: Non-Hodgkin Mantle Cell Lymphomas: Non-Hodgkin Marginal Zone Lymphomas: Non-Hodgkin Peripheral T-Cell Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Interventions Epratuzumab Rituximab

Updated 6 times since 2017 Last updated: May 31, 2011 Started: Nov 30, 2000 Primary completion: Jun 30, 2007 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00398372, this NA trial focuses on Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin and remains completed. Sponsored by Amgen, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
National Institutes of Health (NIH)
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States